vs
Side-by-side financial comparison of Idaho Strategic Resources, Inc. (IDR) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $14.6M, roughly 1.3× Idaho Strategic Resources, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs 64.3%, a 1.5% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 92.0%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 57.2%).
Idaho Strategic Resources, Inc.IDREarnings & Financial Report
Idaho Strategic Resources, Inc. is a U.S.-based natural resource company focused on the exploration, development, and production of critical and strategic minerals. Primarily operating in Idaho, it targets rare earth elements, gold, silver, and other high-demand minerals, supplying products to the clean energy, defense, and industrial manufacturing sectors across North America.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
IDR vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $14.6M | $18.6M |
| Net Profit | $9.4M | $12.3M |
| Gross Margin | 68.5% | — |
| Operating Margin | 62.4% | 56.3% |
| Net Margin | 64.3% | 65.7% |
| Revenue YoY | 92.0% | 1808.5% |
| Net Profit YoY | 220.6% | 376.5% |
| EPS (diluted) | $0.62 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $14.6M | $18.6M | ||
| Q3 25 | $11.1M | $334.0K | ||
| Q2 25 | $9.5M | $1.4M | ||
| Q1 25 | $7.3M | $257.0K | ||
| Q4 24 | $7.6M | $977.0K | ||
| Q3 24 | $6.2M | $660.0K | ||
| Q2 24 | $6.1M | $736.0K | ||
| Q1 24 | $5.9M | $1.4M |
| Q4 25 | $9.4M | $12.3M | ||
| Q3 25 | $3.0M | $-8.6M | ||
| Q2 25 | $2.8M | $-6.9M | ||
| Q1 25 | $1.6M | $-5.4M | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $1.6M | $-2.8M | ||
| Q2 24 | $2.2M | $-14.5M | ||
| Q1 24 | $2.2M | $411.0K |
| Q4 25 | 68.5% | — | ||
| Q3 25 | 63.6% | — | ||
| Q2 25 | 57.8% | — | ||
| Q1 25 | 50.8% | — | ||
| Q4 24 | 53.3% | — | ||
| Q3 24 | 48.7% | — | ||
| Q2 24 | 50.2% | — | ||
| Q1 24 | 48.1% | — |
| Q4 25 | 62.4% | 56.3% | ||
| Q3 25 | 23.4% | -2516.5% | ||
| Q2 25 | 26.6% | -701.0% | ||
| Q1 25 | 19.3% | -3350.2% | ||
| Q4 24 | 36.2% | — | ||
| Q3 24 | 23.4% | -1563.6% | ||
| Q2 24 | 34.2% | -1255.0% | ||
| Q1 24 | 36.3% | -692.5% |
| Q4 25 | 64.3% | 65.7% | ||
| Q3 25 | 26.8% | -2572.2% | ||
| Q2 25 | 29.2% | -504.8% | ||
| Q1 25 | 22.1% | -2097.7% | ||
| Q4 24 | 38.5% | — | ||
| Q3 24 | 25.8% | -425.5% | ||
| Q2 24 | 35.2% | -1964.4% | ||
| Q1 24 | 36.8% | 29.9% |
| Q4 25 | $0.62 | $0.25 | ||
| Q3 25 | $0.20 | $-0.17 | ||
| Q2 25 | $0.20 | $-0.14 | ||
| Q1 25 | $0.12 | $-0.11 | ||
| Q4 24 | $0.21 | — | ||
| Q3 24 | $0.12 | $-0.06 | ||
| Q2 24 | $0.17 | $-0.30 | ||
| Q1 24 | $0.17 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | $2.3M | — |
| Stockholders' EquityBook value | $108.2M | $49.4M |
| Total Assets | $116.2M | $59.0M |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | $6.3M | $73.0M | ||
| Q1 24 | $5.3M | $80.2M |
| Q4 25 | $2.3M | — | ||
| Q3 25 | $3.0M | — | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $1.7M | — | ||
| Q3 24 | $2.9M | — | ||
| Q2 24 | $2.7M | — | ||
| Q1 24 | $3.3M | — |
| Q4 25 | $108.2M | $49.4M | ||
| Q3 25 | $74.3M | $36.4M | ||
| Q2 25 | $49.3M | $44.5M | ||
| Q1 25 | $39.8M | $50.5M | ||
| Q4 24 | $37.7M | $55.1M | ||
| Q3 24 | $33.1M | $58.5M | ||
| Q2 24 | $25.4M | $60.4M | ||
| Q1 24 | $21.6M | $74.1M |
| Q4 25 | $116.2M | $59.0M | ||
| Q3 25 | $83.1M | $51.1M | ||
| Q2 25 | $57.7M | $60.7M | ||
| Q1 25 | $48.1M | $67.9M | ||
| Q4 24 | $44.0M | $90.6M | ||
| Q3 24 | $40.8M | $99.0M | ||
| Q2 24 | $32.2M | $107.8M | ||
| Q1 24 | $28.7M | $118.3M |
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.07× | — | ||
| Q1 25 | 0.09× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.09× | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $10.7M | $18.4M |
| Free Cash FlowOCF − Capex | $8.2M | — |
| FCF MarginFCF / Revenue | 56.0% | — |
| Capex IntensityCapex / Revenue | 17.7% | — |
| Cash ConversionOCF / Net Profit | 1.15× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $12.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.7M | $18.4M | ||
| Q3 25 | $2.4M | $-8.7M | ||
| Q2 25 | $3.5M | $-7.5M | ||
| Q1 25 | $2.4M | $-7.5M | ||
| Q4 24 | $3.2M | $-24.0M | ||
| Q3 24 | $2.5M | $765.0K | ||
| Q2 24 | $2.6M | $-10.9M | ||
| Q1 24 | $2.6M | $-4.0M |
| Q4 25 | $8.2M | — | ||
| Q3 25 | $709.8K | — | ||
| Q2 25 | $2.5M | — | ||
| Q1 25 | $1.0M | — | ||
| Q4 24 | $2.1M | — | ||
| Q3 24 | $1.9M | — | ||
| Q2 24 | $2.4M | — | ||
| Q1 24 | $2.3M | — |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 6.4% | — | ||
| Q2 25 | 26.5% | — | ||
| Q1 25 | 13.8% | — | ||
| Q4 24 | 28.0% | — | ||
| Q3 24 | 30.4% | — | ||
| Q2 24 | 38.7% | — | ||
| Q1 24 | 38.3% | — |
| Q4 25 | 17.7% | — | ||
| Q3 25 | 15.3% | — | ||
| Q2 25 | 10.8% | — | ||
| Q1 25 | 19.4% | — | ||
| Q4 24 | 13.6% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | 5.5% | — |
| Q4 25 | 1.15× | 1.50× | ||
| Q3 25 | 0.81× | — | ||
| Q2 25 | 1.28× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.08× | — | ||
| Q3 24 | 1.56× | — | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 1.19× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IDR
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
